PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-27.41%
Cash & equivalents declining -27.41% while AXSM's grows 205.14%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-27.41%
Below half of AXSM's 205.14%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.07%
Higher Other Current Assets Growth compared to AXSM's zero value, indicating worse performance.
-28.37%
Below half of AXSM's 187.60%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
1187.39%
Below half AXSM's -22.07%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.01%
Less than half of AXSM's -9.64%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
252.00%
Below half of AXSM's -13.56%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-17.83%
Below half of AXSM's 185.46%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-8.53%
1.1-1.25x AXSM's -6.86%. Bill Ackman wonders if the firm relies on extended payables to manage cash flow.
-29.62%
Less than half of AXSM's -83.72%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
12.29%
Below half of AXSM's -0.44%. Michael Burry suspects a big gap in pre-sales traction.
No Data
No Data available this quarter, please select a different quarter.
-3.44%
Less than half of AXSM's -28.76%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7668.72%
Above 1.5x AXSM's 419.91%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
13.42%
Less than half of AXSM's 83.69%. David Dodd sees far fewer liability expansions relative to competitor.
2.97%
Less than half of AXSM's 10.67%. David Dodd sees fewer share issuances vs. competitor.
-3.03%
Below half AXSM's -9.89%. Michael Burry suspects major net losses or high dividends vs. competitor.
25.83%
Higher AOCI Growth compared to AXSM's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-39.38%
Below half AXSM's 116.15%. Michael Burry sees potential underperformance in building shareholder capital.
-17.83%
Below half AXSM's 147.15%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
499.58%
Above 1.5x AXSM's 180.04%. Michael Burry sees a major jump. Investigate leverage rationale.
37.73%
Less than half of AXSM's -229.72%. David Dodd sees better deleveraging or stronger cash buildup than competitor.